scholarly journals A Case Report of Triple-Positive Micropapillary Carcinoma of the Male Breast

Breast Care ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. 192-194 ◽  
Author(s):  
Jamila Shuja ◽  
Iftikhar Ahmad ◽  
Sidra Arshad ◽  
Hina Manzoor ◽  
Shahwali Kakar ◽  
...  
Keyword(s):  
Case Report ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Radical Mastectomy ◽  
Multimodality Treatment ◽  
Lymph Node Involvement ◽  
Male Breast ◽  
Axillary Lymph ◽  
Micropapillary Carcinoma ◽  
Disease Case

Background: Micropapillary carcinoma (MPC), a morphologically distinct subtype of invasive ductal carcinoma, of the male breast is an exceedingly uncommon disease. Case Report: Herein, we report a case of triple-positive MPC of the male breast with axillary lymph node involvement and no recurrence for over 2 years. Specifically, a 60-year-old male patient presented with a hard, elastic, and well-defined painless mass in the right breast. The patient underwent unilateral (right) modified radical mastectomy with axillary clearance. Histopathology revealed MPC grade 3 and metastasis in 16/16 lymph nodes. Hormone receptor analysis demonstrated strong positivity (total score 08) for estrogen/progesterone receptors and overexpression (score 3+) of human epidermal growth factor receptor 2. The patient received adjuvant chemotherapy (6 courses of CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil), radiation, and tamoxifen. The patient has remained disease-free for over 2 years. Conclusion: This study demonstrates that triple-positive MPC of the male breast as a rare malignancy appears to respond promisingly to multimodality treatment.

scholarly journals Trastuzumab induced radiation recall dermatitis: an interesting case

2018 ◽  
Vol 7 (12) ◽  
pp. 2465
Author(s):  
Anupama C. ◽  
Anuradha H. V. ◽  
Vinayak V. Maka
Keyword(s):  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Radical Mastectomy ◽  
Left Breast ◽  
Interesting Case ◽  
Axillary Lymph ◽  
Radiation Recall ◽  
Skin Reactions ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Radiation recall dermatitis (RRD) is the appearance of skin reactions in previously irradiated skin which is triggered by the administration of certain drugs. Surgery, chemotherapy, and radiotherapy are the mainstay of treatment in breast cancer. RRD induced by trastuzumab has been rarely reported in India. This is a case report of a 56-year-old woman presented to the medical oncology outpatient department of our hospital with breast lump, and she was diagnosed to have human epidermal growth factor receptor 2 (HER-2/neu) positive invasive ductal carcinoma of left breast of stage T2N3cM0. She was treated with neoadjuvant chemotherapy, and she underwent modified radical mastectomy with axillary lymph node dissection. The treating oncologist was planned to start on adjuvant chemotherapy with injection trastuzumab for every four weeks, for 15 cycles. Patient received first dose of injection trastuzumab (450 mg) intravenously in the right (contralateral) arm and developed painful, swollen, erythematous blisters, and maculopapular rashes following the sharp linear borders of her previous radiation fields. She was reviewed by the medical oncologist and diagnosed as a rare case of RRD and treated with topical betamethasone cream. Causality assessment for RRD to trastuzumab was done using Naranjo and WHO-UMC scale and found to be in the category of probable and probable/ likely respectively.

scholarly journals Management and Outcomes of Male Breast Cancer in Zaria, Nigeria

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Adamu Ahmed ◽  
Yahaya Ukwenya ◽  
Adamu Abdullahi ◽  
Iliyasu Muhammad
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Advanced Disease ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Tumor Diameter ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Modified Radical Mastectomy ◽  
Male Patients

Male breast cancer is an uncommon disease accounting for only 1% of all breast cancers. We present the evaluation, treatment and outcome of male patients seen with breast cancer in our institution. Male patients that had histological diagnosis of breast cancer from 2001 to 2010 were retrospectively evaluated. After evaluation patients were treated with modified radical mastectomy. Combination chemotherapy was given to patients with positive axillary lymph nodes. Radiotherapy and hormonal therapy were also employed. There were 57 male patients with breast cancer which accounted for 9% of all breast cancers seen during the study period. Their mean age was 59 ± 2.3 years. The mean tumor diameter was 13 ± 2.5 cm. Fifty three (93%) patients presented with advanced disease including 15 with distant metastasis. Four patients with stage II disease were treated with modified radical mastectomy, chemotherapy and tamoxifen. Of the 30 patients with sage III disease that had modified radical mastectomy, complete axillary clearance and tumor free margins were achieved in 25. Overall 21 (36.8%) patients were tumor free at one year. Overall 5-year survival was 22.8%. In conclusion, male patients with breast cancer present with advanced disease which is associated with poor outcome of treatment.

Primary invasive breast cancer in 104 women: A single-center experience in the years 1995–2005

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11093-11093
Author(s):  
M. Beda ◽  
C. Ghiotto ◽  
U. Basso ◽  
M. Stefani ◽  
S. Lonardi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Genetic Testing ◽  
Mutational Analysis ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
P53 Mutation ◽  
Age At Menarche ◽  
Axillary Lymph ◽  
Prophylactic Measures ◽  
Lh Rh

11093 Background: To assess clinical, genetic and biological characteristics of breast cancer (BC) in women £ 35 years followed in a single Institution, along with patterns of disease recurrence and survival. Materials and Methods: All consecutive women £ 35 years with invasive BC registered at our Medical Oncology Department between 1995 and 2005 were enrolled in this retrospective analysis. Genetic testing for BRCA1/2 and P53 started in the year 2000. Results: Out of 4.120 cases, a total of 104 pts were identified, median age 32 years (range 22–35). Median age at menarche was 13 years, 48% were nulliparous. Approximately on third reported oral contraceptive use, while 23% reported a family history of BC. Almost 90% had a self -diagnosis of disease. Modified radical mastectomy was performed in 48%, conservative surgery in 46%, 6 metastatic pts were not operated. Axillary lymph node involvement was present in one half of cases. The prevalent histology was ductal carcinoma, 78% G2-G3, 26% hormone-receptor negative, 43% HER-2 positive. TNM stage was 29% I, 39% II, 22% III, 10% IV. Neo-adjuvant or adjuvant anthracycline based chemotherapy was administered to 86.7% of patients, combined with taxanes in 23% of cases. Twenty-four patients developed amenorrhea after stopping chemotherapy, the other ER/PgR positive patients received LH-RH analogues for 2 years. Tamoxifen was given to all ER/PgR positive patients. Genetic mutational analysis was available in 43 patients, and 9 mutations of BRCA 1 and 4 of BRCA 2 were found; two patients had a p53 mutation and one of them had an overt Li-Fraumeni syndrome. After a median follow-up of 5.5 years, 29 patients (28%) have recurred and 13 (12.5%) have died, with an estimated 5 year-DFS and OS of 82.4% and 87.5%, respectively. Conclusions: Our data confirm the aggressive biological features of BC in very young women. Intensive chemotherapy produces amenorrhea in 31% of cases. The 35% rate of BRCA1/2 or p53 mutation justifies a broader use of genetic testing in such patients in order to evaluate prophylactic measures for the female relatives. No significant financial relationships to disclose.

Plasmacytoma in the Breast with Axillary Lymph Node Involvement: A Case Report

2006 ◽  
Vol 7 (1) ◽  
pp. 81-84 ◽  
Author(s):  
Lesley Taylor ◽  
Mohamad Aziz ◽  
Paula Klein ◽  
Amitabha Mazumder ◽  
Sundar Jagannath ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Node Involvement ◽  
Axillary Lymph Node Involvement

scholarly journals Association of axillary node status with clinicopathological characteristics and expression of EZH2 and CD44 in primary breast ductal carcinoma

2020 ◽  
Vol 36 (7) ◽  
Author(s):  
Miodrag Djordjevic ◽  
Aleksandar Karanikolic ◽  
Ljubinka Velickovic ◽  
Maja Milentijevic
Keyword(s):  
Ductal Carcinoma ◽  
Expression Profiles ◽  
Univariate Analysis ◽  
Radical Mastectomy ◽  
Clinicopathological Characteristics ◽  
Axillary Node ◽  
Disease Stage ◽  
Endocrine Surgery ◽  
Axillary Lymph ◽  
Node Status

Objective: In order to enhance the prognostic benefit of new molecular markers, the aim of this study was to identify possible association of axillary lymph node (ALN) status and pN with clinicopathological characteristics and expression of EZH2 and CD44 in invasive ductal carcinoma (IDC) of the breast. Methods: The investigation included 106 patients with IDC who had undergone radical mastectomy at the Clinic of Endocrine Surgery in Nis. Clinicopathologic parameters and immunohistochemical expression of EZH2 and CD44 in primary IDC were investigated in relation to ALN status and pN. Results: Our univariate analysis established that Т3-Т4 stage, high EZH2, and high EZH2 with ER- were associated with ALN metastasis (p=0.014; 0.003; 0.013). Decreased probability for ALN involvement was found with Т1 stage, and low EZH2 with ER+ (p=0.032; 0.022). Multivariant analysis established that high EZH2 in cancer cells was associated with high risk for ALN metastases (p=0.004); T1 tumors were associated with low risk (p=0.037). Higher pN was associated with high EZH2, high EZH2 with ER-, as well as an advanced clinical and disease stage (p=0.006; 0.001; p=0.002, 0.001). Lower pN was associated with ER+, and ER+ with low EZH2 (p= 0.004; 0.012). CD44 was not associated with ALN involvement, nor with pN. Conclusions: This study revealed association of EZH2 with ALN metastases, where disease stage and expression profiles of EZH2 and ER may have affected regional pN. doi: https://doi.org/10.12669/pjms.36.7.2954 How to cite this:Djordjevic M, Karanikolic A, Velickovic L, Milentijevic M. Association of axillary node status with clinicopathological characteristics and expression of EZH2 and CD44 in primary breast ductal carcinoma. Pak J Med Sci. 2020;36(7):---------.   doi: https://doi.org/10.12669/pjms.36.7.2954 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Invasive Micropapillary Carcinoma of the Male Breast—A Case Report—

2017 ◽  
Vol 78 (7) ◽  
pp. 1485-1489
Author(s):  
Sadatoshi SUGAE ◽  
Hidetaka SHIMA ◽  
Kazutaka NARUI ◽  
Makiko ENAKA ◽  
Yasushi ICHIKAWA ◽  
...  
Keyword(s):  
Case Report ◽  
Male Breast ◽  
Invasive Micropapillary Carcinoma ◽  
Micropapillary Carcinoma

Invasive Ductal Carcinoma of the Male Breast: A Case Report and Review of the Literature

2002 ◽  
Vol 34 (3) ◽  
pp. 239-242
Author(s):  
Jinyoung Yoo ◽  
Hyun Joo Choi ◽  
Hee Jeong Lee ◽  
Seok Jin Kang ◽  
Byung Kee Kim ◽  
...  
Keyword(s):  
Case Report ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Male Breast ◽  
Review Of The Literature

scholarly journals Intracystic Papillary Carcinoma in the Male Breast: A Rare Endpoint of a Wide Spectrum

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Ketan Vagholkar ◽  
Khojasteh Dastoor ◽  
Indumati Gopinathan
Keyword(s):  
Case Report ◽  
Papillary Carcinoma ◽  
Wide Spectrum ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Therapeutic Options ◽  
Modified Radical Mastectomy ◽  
Fibrocystic Disease ◽  
Axillary Clearance ◽  
Intracystic Papillary Carcinoma

Introduction. Fibrocystic disease of the male breast is uncommon. The presence of a spectrum of changes ranging from fibrocystic disease to duct papilloma to papillary carcinoma in the same patient renders the case a rarity and therefore reportable.Case Report. A case of intracystic papillary carcinoma of the male breast is presented.Discussion. The pathological, clinical, diagnostic, and therapeutic options are discussed after reviewing the literature.Conclusion. Modified radical mastectomy with axillary clearance is the safest option for established cases.

scholarly journals Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 119
Author(s):  
Andra Piciu ◽  
Doina Piciu ◽  
Narcis Polocoser ◽  
Anita A. Kovendi ◽  
Iulia Almasan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Distant Metastases ◽  
Lymph Node Involvement ◽  
Male Breast ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Node Involvement ◽  
Male Patients ◽  
Fdg Pet Ct

Introduction: F18-FDG PET/CT is the most important hybrid imaging used in the diagnostic, staging, follow-up, and treatment evaluation response in cancer patients. However, it is well-known that in breast cancer the use of F18-FDG is not included in the first line protocol of initial diagnostic, both in female and male breast cancer patients. F18-FDG PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases, and other occult primary cancers. This study assesses F18-FDG PET/CT systemic staging in male patients with diagnosed breast cancer and determines detection rates for unsuspected distant metastases and synchronous malignancies. Methods: We analyzed a number of 170 male patients with breast cancer, seen between 2000–2020, in a tertiary center. From this group, between 2013–2020 a number of 23 patients underwent F18-FDG PET/CT. Rates of upstaging were determined for each case and the detection of other primary malignancies was analyzed. Results: Median age of male breast cancer group was 61.3 y (range, 34–85 y), most had intraductal carcinoma (82.4%) and unsuspected distant metastases, which increased patient stage to IV, observed in 27%. In 4 out 23 patients (17.4%), F18-FDG PET/CT identified synchronous cancers (2 prostate cancers, 1 thyroid and 1 colon cancer). Conclusion: F18-FDG PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases, and other occult primary cancers. Baseline F18-FDG PET/CT has a substantial impact on the initial staging and on clinical management in male breast patients and should be considered for use in newly diagnosed patients.

Sign in / Sign up

Export Citation Format

Share Document